Open & Closed Studies
Cardiovascular
Clinical Research & TrainingCLOSED FOR ENROLLMENT: Study to Evaluate the Effect of Dapagliflozin on the Incidence of worsening Heart Failure or Cardiovascular Death in Patients with Chronic Heart Failure with Reduced Ejection Fraction.
OPEN FOR ENROLLMENT: A multicenter, randomized, double-blind, double-dummy, parallel-group, active-controlled, forced-titration, 12-week comparison of combined angiotensin-neprilysin inhibition with sacubitril and valsartan versus enalapril on changes in central aortic stiffness in patients with heart failure and reduced ejection fraction (HFrEF): EVALUATE-HF.
OPEN FOR ENROLLMENT: A multicenter, randomized, double-blind, double-dummy, parallel-group, active-controlled, forced-titration, 12-week comparison of combined angiotensin-neprilysin inhibition with sacubitril and valsartan versus enalapril on changes in central aortic stiffness in patients with heart failure and reduced ejection fraction (HFrEF): EVALUATE-HF.
Neurosciences
Clinical ResearchOPEN FOR ENROLLMENT: A Multicenter, Randomized, Double-blind, Sham-controlled, Comparative Study of SI-6603/1133 in Patients with Lumbar Disc Herniation (Phase III).
ENROLLMENT CLOSED/ON FOLLOW-UP ONLY: A Multicenter, Open-Label Study of SI-6603/1132 in Patients with Lumbar Disc Herniation (Phase III).
CLOSED: A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of AXS-02 (Disodium Zoledronate Tetrahydrate) Administered Orally to Subjects with Complex Regional Pain Syndrome Type I (CRPS-I).
ENROLLMENT CLOSED/ON FOLLOW-UP ONLY: A Multicenter, Open-Label Study of SI-6603/1132 in Patients with Lumbar Disc Herniation (Phase III).
CLOSED: A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of AXS-02 (Disodium Zoledronate Tetrahydrate) Administered Orally to Subjects with Complex Regional Pain Syndrome Type I (CRPS-I).
Gastroenterology
Clinical ResearchOPEN FOR ENROLLMENT:A Phase III, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biological-Failed Patients with Moderately to Severely Active Ulcerative Colitis
A Phase IIB, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Multicenter Study to Assess Efficacy and Safety of SER-287 in Adults with Active Mild-to-Moderate Ulcerative Colitis
A Phase IIB, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Multicenter Study to Assess Efficacy and Safety of SER-287 in Adults with Active Mild-to-Moderate Ulcerative Colitis
Gastroenterology (cont.)
Clinical ResearchOPEN FOR ENROLLMENT: Shire Human Genetic Therapies, Inc. (``Shire``) / ``A Phase III Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647-302 as Induction Therapy in Subjects with Moderate to Severe Ulcerative Colitis (FIGARO UC 302) ``
A Phase III Long-term Safety Extension Study of SHP647 in Subjects with Moderate to Severe Ulcerative Colitis (AIDA)
A Phase III Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety of SHP647-306 as Induction Therapy in Subjects with Moderate to Severe Crohn's Disease (CARMEN CD 306)
A Phase III Long-term Safety Extension Study of SHP647 in Subjects with Moderate to Severe Ulcerative Colitis (AIDA)
A Phase III Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety of SHP647-306 as Induction Therapy in Subjects with Moderate to Severe Crohn's Disease (CARMEN CD 306)